News Release: Farpoint Development and The Landes Group Acquire 175,000 SF On-Campus Medical Office Building in One of Chicago’s Fastest-Growing Suburbs

Chicago-based Farpoint Development and Dallas-based The Landes Group have closed on the acquisition of Pavilion A, a premier 175,000-square-foot, on-campus medical office building at Silver Cross Hospital in New Lenox, Illinois. The purchase expands the firms’ partnership focused on delivering long-term real estate solutions for health systems nationwide. The PGIM Real Estate was the seller.

About Farpoint Development

At Farpoint Development, we do more than build buildings. Our founders have decades of experience solving real estate challenges by creatively and carefully answering the needs of our partners. Our ambition to build resilient, sustainable neighborhoods — places that people will be proud to work or live in decades from now — is what drove us to find our firm. It’s also what drives us forward. We design for the long-term with buildings that are resilient and sustainable. We approach our work with optimism. It’s why we embrace complex projects that anchor entire neighborhoods. We prioritize relationships over profit. In fact, we believe that strong partnerships — with all our stakeholders — generate stronger financial results.

About The Landes Group

The Landes Group is a Dallas-based real estate investment firm specializing in tailored, cost effective financing strategies that create aligned partnerships and maximize long-term tenant value. Through a disciplined and collaborative approach, the firm structures capital solutions that bring tenants, developers, and capital partners into true economic alignment.

With over 35+years of experience, The Landes Group and its affiliates have completed more than $27 billion in transactions across 6,000+ properties nationwide and have pioneered financing structures that are widely used today.

The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE

Existing Users Log In